Search

AF solution

Chevron

Macrophage

A co-culturing platform of macrophages and organoids demonstrates varying organoid cytotoxic effects depending on the ratio of M1 macrophages to M2 macrophages.
Optimal cell death effects are established by co-culturing different ratios of functionally diverse immune cells.
This enables the identification of optimal conditions for co-culturing various immune cells, facilitating the selection of an appropriate platform for drug testing.

Starting cost
€ 0 +

Macrophage

Colorectal cancer organoids accurately replicate the complexities of patient tumors, including heterogeneity,
genetic traits, and tissue structure.
These organoids serve as a versatile platform for drug testing, allowing the evaluation of drug responses and sensitivity.
Additionally, they facilitate personalized disease modeling using patient-specific samples, contributing to biomarker identification for prognosis and treatment response.

NSCLC organoids, reflecting the heterogeneity and genetic features of patient tumors, provide a versatile platform for in-depth cancer research.
These organoids faithfully mimic the tissue architecture of NSCLC, facilitating the study of tumor dynamics, invasion patterns, and drug responses.
Their patient-specific modeling capability allows personalized exploration of treatment outcomes.

Experiment

Macrophage

The co-culture drug evaluation solution with macrophages, T cells, and cancer organoids allows for the simultaneous observation of the phagocytic activity of macrophages and the cytotoxic ability of T cells.
Co-culturing with both M1 and M2 macrophages is possible, mimicking the role of macrophages observed in actual cancer tissues.

Process